Producing therapeutic peptides using biotechnology

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.

whitePaper | November 12, 2019

This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

whitePaper | August 19, 2021

DNA storage technology is advancing rapidly. Atos is closely monitoring the development of this technology in the hope that future developments will make it a scalable, cost effective and crucially a decarbonized alternative to today’s carbon intensive technologies.